voorkomen afstoting na niertransplantatie kidney transplantation
Conditions
Interventions
All participants will receive the tacrolimus starting dose based on a dosing
algorithm which bases the dose on body surface area, CYP3A4 and CYP3A5
genotype, and age, rather than the standard bodywe
Sponsors
Erasmus MC, Universitair Medisch Centrum Rotterdam
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: * Age * 18 years old * Patients receiving a kidney from a living donor (related or unrelated) * Patients receiving a kidney from a blood group AB0-compatible donor * Patients receiving a kidney form an HLA-compatible donor (non-desensitized patients) * Patients who will receive tacrolimus as part of the initial immunosuppressive therapy * Signed written informed consent
Exclusion criteria
Exclusion criteria: * Recipients of a non-renal organ transplant at the same occasion * Recipients receiving immunosuppressive therapy (except steroid treatment) within the preceding 28 days. * Recipients using medication known to have a pharmacokinetic interaction with tacrolimus
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main study endpoint of the study is the proportion of patients reaching the target C0 (7.5-12.5 ng/mL) on day 3. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary study endpoints of the study are: * The proportion of patients reaching the target C0 (7.5-12.5 ng/mL) on day 5, 7 and 10. * The proportion of patients with markedly supra- (>20 ng/mL) or sub-therapeutic ( | — |
Countries
Netherlands
Outcome results
None listed